MX2023014709A - Inhibidores de la recaptacion de norepinefrina para tratamiento de la apnea del sue?o. - Google Patents
Inhibidores de la recaptacion de norepinefrina para tratamiento de la apnea del sue?o.Info
- Publication number
- MX2023014709A MX2023014709A MX2023014709A MX2023014709A MX2023014709A MX 2023014709 A MX2023014709 A MX 2023014709A MX 2023014709 A MX2023014709 A MX 2023014709A MX 2023014709 A MX2023014709 A MX 2023014709A MX 2023014709 A MX2023014709 A MX 2023014709A
- Authority
- MX
- Mexico
- Prior art keywords
- norepinephrine reuptake
- sleep apnea
- reuptake inhibitors
- treating sleep
- optionally
- Prior art date
Links
- 239000002767 noradrenalin uptake inhibitor Substances 0.000 title abstract 3
- 229940127221 norepinephrine reuptake inhibitor Drugs 0.000 title abstract 3
- 201000002859 sleep apnea Diseases 0.000 title abstract 2
- YWPHCCPCQOJSGZ-LLVKDONJSA-N (2r)-2-[(2-ethoxyphenoxy)methyl]morpholine Chemical compound CCOC1=CC=CC=C1OC[C@@H]1OCCNC1 YWPHCCPCQOJSGZ-LLVKDONJSA-N 0.000 abstract 1
- 206010041235 Snoring Diseases 0.000 abstract 1
- CPBHSHYQQLFAPW-ZWKOTPCHSA-N edivoxetine Chemical compound COC1=CC=C(F)C=C1C[C@](O)([C@H]1OCCNC1)C1CCOCC1 CPBHSHYQQLFAPW-ZWKOTPCHSA-N 0.000 abstract 1
- 229950003015 edivoxetine Drugs 0.000 abstract 1
- 238000000034 method Methods 0.000 abstract 1
- 239000003149 muscarinic antagonist Substances 0.000 abstract 1
- 239000008194 pharmaceutical composition Substances 0.000 abstract 1
- 238000009097 single-agent therapy Methods 0.000 abstract 1
- 229960001255 viloxazine Drugs 0.000 abstract 1
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/535—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with at least one nitrogen and one oxygen as the ring hetero atoms, e.g. 1,2-oxazines
- A61K31/5375—1,4-Oxazines, e.g. morpholine
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/21—Esters, e.g. nitroglycerine, selenocyanates
- A61K31/215—Esters, e.g. nitroglycerine, selenocyanates of carboxylic acids
- A61K31/216—Esters, e.g. nitroglycerine, selenocyanates of carboxylic acids of acids having aromatic rings, e.g. benactizyne, clofibrate
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
- A61K31/496—Non-condensed piperazines containing further heterocyclic rings, e.g. rifampin, thiothixene or sparfloxacin
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/535—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with at least one nitrogen and one oxygen as the ring hetero atoms, e.g. 1,2-oxazines
- A61K31/5375—1,4-Oxazines, e.g. morpholine
- A61K31/5377—1,4-Oxazines, e.g. morpholine not condensed and containing further heterocyclic rings, e.g. timolol
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/0012—Galenical forms characterised by the site of application
- A61K9/0053—Mouth and digestive tract, i.e. intraoral and peroral administration
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P11/00—Drugs for disorders of the respiratory system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P11/00—Drugs for disorders of the respiratory system
- A61P11/04—Drugs for disorders of the respiratory system for throat disorders
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K2300/00—Mixtures or combinations of active ingredients, wherein at least one active ingredient is fully defined in groups A61K31/00 - A61K41/00
Landscapes
- Health & Medical Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Medicinal Chemistry (AREA)
- Pharmacology & Pharmacy (AREA)
- Life Sciences & Earth Sciences (AREA)
- Animal Behavior & Ethology (AREA)
- General Health & Medical Sciences (AREA)
- Public Health (AREA)
- Veterinary Medicine (AREA)
- Epidemiology (AREA)
- Pulmonology (AREA)
- General Chemical & Material Sciences (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Organic Chemistry (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Engineering & Computer Science (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Emergency Medicine (AREA)
- Otolaryngology (AREA)
- Physiology (AREA)
- Nutrition Science (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
- Medicinal Preparation (AREA)
Applications Claiming Priority (3)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US202163211673P | 2021-06-17 | 2021-06-17 | |
| US202263319035P | 2022-03-11 | 2022-03-11 | |
| PCT/US2022/033987 WO2022266440A1 (en) | 2021-06-17 | 2022-06-17 | Norepinephrine reuptake inhibitors for treating sleep apnea |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| MX2023014709A true MX2023014709A (es) | 2024-01-15 |
Family
ID=82608262
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| MX2023014709A MX2023014709A (es) | 2021-06-17 | 2022-06-17 | Inhibidores de la recaptacion de norepinefrina para tratamiento de la apnea del sue?o. |
Country Status (10)
| Country | Link |
|---|---|
| US (1) | US20240277719A1 (cg-RX-API-DMAC7.html) |
| EP (1) | EP4355333A1 (cg-RX-API-DMAC7.html) |
| JP (1) | JP2024523876A (cg-RX-API-DMAC7.html) |
| KR (1) | KR20240021920A (cg-RX-API-DMAC7.html) |
| AU (1) | AU2022294086A1 (cg-RX-API-DMAC7.html) |
| BR (1) | BR112023026158A2 (cg-RX-API-DMAC7.html) |
| CA (1) | CA3221848A1 (cg-RX-API-DMAC7.html) |
| IL (1) | IL309251A (cg-RX-API-DMAC7.html) |
| MX (1) | MX2023014709A (cg-RX-API-DMAC7.html) |
| WO (1) | WO2022266440A1 (cg-RX-API-DMAC7.html) |
Families Citing this family (1)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| WO2025106773A1 (en) * | 2023-11-17 | 2025-05-22 | Apnimed, Inc. (Delaware) | Methods and compositions for treating sleep apnea with a combination of a glp-1 agonist and a second active agent |
Family Cites Families (9)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US4522811A (en) | 1982-07-08 | 1985-06-11 | Syntex (U.S.A.) Inc. | Serial injection of muramyldipeptides and liposomes enhances the anti-infective activity of muramyldipeptides |
| WO2006023703A2 (en) * | 2004-08-20 | 2006-03-02 | Cypress Bioscience, Inc. | Method for treating sleep related breathing disorders |
| WO2008157094A1 (en) * | 2007-06-13 | 2008-12-24 | Cypress Bioscience, Inc. | Improving the tolerability of mirtazapine and a second active by using them in combination |
| CN119185558A (zh) * | 2017-04-28 | 2024-12-27 | 布里格姆妇女医院 | 用于治疗睡眠呼吸暂停的方法和组合物 |
| CN111670050A (zh) * | 2018-01-30 | 2020-09-15 | 爱普宁公司(特拉华) | 用于治疗睡眠呼吸暂停的方法和组合物 |
| CA3117766A1 (en) * | 2018-10-31 | 2020-05-07 | Apnimed, Inc. (Delaware) | Methods and compositions for treating sleep apnea |
| ES3049086T3 (en) * | 2019-02-08 | 2025-12-12 | Brigham & Womens Hospital Inc | Methods and compositions for treating sleep apnea |
| US20220362221A1 (en) * | 2019-11-04 | 2022-11-17 | Apnimed, Inc. (Delaware) | Combination pharmacological interventions for multiple mechanisms of obstructive sleep apnea |
| US20240075035A1 (en) * | 2021-01-14 | 2024-03-07 | Apnimed, Inc. (Delaware) | Methods and compositions for treating sleep apnea |
-
2022
- 2022-06-17 JP JP2023577376A patent/JP2024523876A/ja active Pending
- 2022-06-17 IL IL309251A patent/IL309251A/en unknown
- 2022-06-17 KR KR1020247001376A patent/KR20240021920A/ko active Pending
- 2022-06-17 MX MX2023014709A patent/MX2023014709A/es unknown
- 2022-06-17 BR BR112023026158A patent/BR112023026158A2/pt unknown
- 2022-06-17 US US18/570,673 patent/US20240277719A1/en active Pending
- 2022-06-17 WO PCT/US2022/033987 patent/WO2022266440A1/en not_active Ceased
- 2022-06-17 CA CA3221848A patent/CA3221848A1/en active Pending
- 2022-06-17 AU AU2022294086A patent/AU2022294086A1/en active Pending
- 2022-06-17 EP EP22743989.0A patent/EP4355333A1/en active Pending
Also Published As
| Publication number | Publication date |
|---|---|
| KR20240021920A (ko) | 2024-02-19 |
| EP4355333A1 (en) | 2024-04-24 |
| US20240277719A1 (en) | 2024-08-22 |
| WO2022266440A1 (en) | 2022-12-22 |
| CA3221848A1 (en) | 2022-12-22 |
| BR112023026158A2 (pt) | 2024-03-05 |
| JP2024523876A (ja) | 2024-07-02 |
| IL309251A (en) | 2024-02-01 |
| AU2022294086A1 (en) | 2024-01-04 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| MX2024001713A (es) | Metodos y composiciones para tratar la apnea del sue?o. | |
| AU2008267058A8 (en) | Treatment of pulmonary hypertension with carbonic anhydrase inhibitors in combination with a sympathomimetic amine | |
| MX2008011633A (es) | Aminoquinolonas como inhibidores de gsk-3. | |
| MX2021001807A (es) | Combinacion de un inhibidor de histona desacetilasa y un inhibidor de proteina cinasa y uso farmaceutico de la misma. | |
| BRPI0408902A (pt) | composições de inibidores seletivos da ciclooxigenase-2 e agonistas de 5-ht 1b/1d para o tratamento e a prevenção de enxaqueca | |
| MX2015012760A (es) | Composicion farmaceutica que comprende un activador de ampk y un agente serotonergico y metodos de uso de la misma. | |
| MY196599A (en) | Pharmaceutical compositons comprising n-(3,5-dimethoxyphenyl)-n'-(1-methylethyl)-n-[3-(1-methyl-1h-pyrazol-4-yl)quinoxalin-6-yl]ethane-1,2-diamine | |
| EA200802390A1 (ru) | Конъюгаты аналогов азиридилэпотилона и фармацевтические композиции, содержащие их | |
| WO2008024439A3 (en) | 4-aminoquinazoline derivatives and methods of use thereof | |
| MX2010009623A (es) | Derivados de 1-bencil-3-hidroximetilindazol novedosos y su uso en el tratamiento de enfermedades basadas en la expresion de mcp-1, cx3cr1 y p40. | |
| MX2010009625A (es) | Derivados de 1-bencil-3-hidroximetilindazol y uso de los mismos en el tratamiento de enfermedades basadas en la expresion de mcp-1, cx3cr1 y p40. | |
| ZA202212095B (en) | Il4i1 inhibitors and methods of use | |
| WO2008042480A3 (en) | Epoxide inhibitors of cysteine proteases | |
| WO2020047352A8 (en) | Plasma kallikrein inhibitors and uses thereof for treating hereditary angioedema attack | |
| MX2010002667A (es) | Cianoaminoquinolonas y tetrazoloaminoquinolonas como inhibidores de gsk-3. | |
| MX2022009197A (es) | Metodos de tratamiento para deficiencia de alfa-1 antitripsina. | |
| EA202192202A1 (ru) | Способы и композиции для лечения синдрома обструктивного апноэ, возникающего во сне | |
| WO2008070010A3 (en) | Hydroxylamine derivatives for the treatment of stroke | |
| MX2024013184A (es) | Metodos y composiciones para tratar apnea del sue?o | |
| MX2022007113A (es) | Inhibidores de la desmetilasa de la histona especifica de la lisina para el tratamiento de las neoplasias mieloproliferativas. | |
| CA3265870A1 (en) | Pharmaceutical compositions based on topoisomerase-1 inhibitors derived from Exatecan, and their uses | |
| MX2023014704A (es) | Inhibidores de proteasa para el tratamiento de infecciones por coronavirus. | |
| CR10253A (es) | "inhibidores de pai-1 para tratamiento de afecciones musculares" | |
| MX2021005944A (es) | Inhibidores de rip1. | |
| MX2022012001A (es) | Tratamiento preventivo de la migra?a. |